Multi-center Randomized Study Comparing Subsegmental and Segmental InterVapor Treatment for Severe Emphysema
Led by Shanghai Chest Hospital · Updated on 2025-09-08
100
Participants Needed
9
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of two different approaches to bronchoscopic thermal vapor ablation BTVA treatment using the InterVapor System in patients with severe emphysema. The study compares treating at least two subsegments in different lung segments versus treating at least one whole lung segment. This multi-center randomized controlled trial aims to provide precise treatment options for patients with severe emphysema while continuing optimal medical therapy.
Participants are randomly assigned to one of two groups the experimental group receives BTVA treatment targeting at least two subsegments of different lung segments in a single procedure, while the control group receives treatment targeting at least one whole segment per procedure. Each patient undergoes a sequential treatment with a minimum of 6 weeks and up to 6 months between procedures, with a maximum treatment volume defined per procedure and cumulatively across two treatments. Alongside BTVA, all participants continue receiving medical therapy following GOLD guidelines throughout the study.
During the study, patients will have follow-up visits at 1, 3, 6, and 12 months after the second procedure. These visits include tests to assess lung function, high-resolution CT scans, a 6-minute walk test, and questionnaires measuring quality of life and respiratory symptoms. The main outcome being evaluated is lung function improvement measured by FEV1 six months after the second procedure. Secondary outcomes include lung volume changes, other lung function measures, exercise capacity, symptom assessments, responder rates, and recording of any adverse events during and up to one year after treatment.
CONDITIONS
Brief Title
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
Research Team
J
Jiayuan Sun, MD., PhD.
H
Huan Hou, MD., PhD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of severe emphysema with at least two treatable subsegments and one treatable segment in the same lung confirmed by quantitative CT
Non-smoking for at least 2 months prior to enrollment and willing to remain abstinent during the study
Forced expiratory volume in 1 second (FEV1) between 15% and 50% of predicted, total lung capacity (TLC) at least 100% predicted, residual volume (RV) at least 150% predicted, and RV/TLC ratio at least 55%
Ability to walk more than 140 meters in 6-minute walk test (or exemption if having lower limb disability)
Modified Medical Research Council (mMRC) dyspnea score of 2 or higher
Arterial blood gas levels: PaCO2 less than or equal to 55 mmHg and PaO2 greater than 50 mmHg on room air
Mentally and physically able to cooperate with study procedures and provide informed consent
You will not qualify if you...
Contraindications to bronchoscopy such as recent myocardial infarction (within 1 month), unstable myocardial ischemia, ejection fraction 40% or less, active bleeding in lungs, coagulation disorders, malignant arrhythmia, severe pulmonary hypertension, or extreme systemic failure
Other illnesses or medications increasing risk from InterVapor treatment, including immune disorders, immunosuppressant drugs, bleeding disorders, unstable cardiovascular conditions, asthma, or alpha-1 antitrypsin deficiency
Use of morphine derivatives within 4 weeks before screening
Use of more than 10 mg prednisolone or equivalent daily glucocorticoids at screening
COPD exacerbation within 6 weeks prior to screening
Severe emphysema in both upper and lower lobes of the opposite lung exceeding 40% volume by HRCT
Presence of large bullae or paraseptal emphysema in target lobe
Active infection or symptoms such as fever or elevated white blood cells
History of lung or heart transplant, lung volume reduction surgery, thoracic surgeries involving lung tissue removal, or endobronchial lung volume reduction
Suspicious malignant pulmonary nodules
Pregnancy or breastfeeding
Participation in other investigational studies not yet completed
Any condition deemed inappropriate by investigators for enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - At least 6 weeks and up to 6 months between first and second procedures
Participants receive BTVA treatment with the InterVapor System in either subsegments or segments of the lung, followed by optimal medical therapy according to GOLD guidelines.
2 procedures with a sequential interval between 6 weeks and 6 months
Follow-up
Duration - 12 months following the second procedure
Participants attend follow-up visits for assessment of lung function, imaging tests, exercise capacity, quality of life, and monitoring of adverse events.
Visits at 1, 3, 6, and 12 months after the second procedure
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Multi-center Randomized Study Comparing Subsegmental and Segmental InterVapor Treatment for Severe Emphysema
Observational Study of Bronchoscopic Lung Volume Reduction Using Zephyr Endobronchial Valve in Severe Emphysema Patients Across Japan
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Study protocol for a multicentre, randomised controlled trial in China to evaluate the efficacy and safety of precise subsegmental bronchoscopic thermal vapour ablation treatment in severe emphysema.
Association Between Subsegmental Dosing Accuracy and Outcomes of Bronchoscopic Thermal Vapor Ablation: An Exploratory Retrospective Study in Severe Heterogeneous Emphysema.